Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – April 11, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA
Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.

A. March 14, 2012 DUR Minutes – Vote
B. March 15, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.

A. Retrospective Drug Utilization Review for December 2011
B. Retrospective Drug Utilization Review Response for October 2011
C. Medication Coverage Activity for March 2012

Items to be presented by Dr. Martinez, Dr. Muchmore, Chairman

5. Genetic Technologies in Health Care – Presented by Alison Adams Martinez, Ph.D., OHCA Clinical Data Analyst

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

6. Action Item – Vote to Prior Authorize Kalydeco™ – See Appendix C.

A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

7. Action Item – Annual Review of Growth Hormones – See Appendix D.

A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorization Review
D. Market News and Updates
E. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. FY 2011 Annual Review – See Appendix E.

A. Top 100 Medications by Total Pharmacy Reimbursement
B. Top 50 Medications by Number of Pharmacy Claims
C. Pharmacy Claims Comparison by Therapeutic Category

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. Action Item – Questions Regarding Annual Review of Requip XL® and Mirapex ER® – See Appendix F.

A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorization Review
D. Market News and Updates
E. COP Recommendations
F. Utilization Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. Action Item – Questions Regarding Annual Review of Metazolv® – See Appendix G.

A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorization Review
D. Market News and Updates
E. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. FDA and DEA Updates – See Appendix H.

12. Future Business

A. Annual Review of Atypical Antipsychotics
B. Annual Review of NSAIDs
C. New Product Reviews
D. Medical Product Reviews

13. Adjournment